Insmed to Host Webinar on June 4, 2024

Insmed Incorporated, a leading global biopharmaceutical firm focused on serious and rare diseases, is set to hold a commercial webinar on June 4, 2024, at 8:00 a.m. ET. The session will address the market outlook for the company's three primary programs: ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP).

Stakeholders can join the discussion by calling (800) 715-9871 in the U.S. or (646) 307-1963 internationally, using the access code 7504027. The webinar will also be live-streamed on Insmed's website. For those who miss the live event, a replay will be available for a month by dialing (800) 770-2030 in the U.S. or (609) 800-9909 internationally, referencing the same access code. The webcast will be accessible on the company's website for 90 days.

ARIKAYCE has received approvals across multiple regions, including the U.S., Europe, and Japan. It is an inhalable form of amikacin, traditionally used intravenously but known for its severe side effects like ototoxicity and nephrotoxicity. Insmed’s PULMOVANCE® technology facilitates direct delivery of amikacin to the lungs, minimizing systemic exposure and targeting lung macrophages where the infection resides. The drug is administered via the Lamira® Nebulizer System, designed by PARI Pharma GmbH.

Safety information and adverse reactions to ARIKAYCE were highlighted during clinical trials. Hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbations of underlying pulmonary diseases were more frequent in patients treated with ARIKAYCE plus a background regimen compared to those treated with a background regimen alone. In cases of ototoxicity, nephrotoxicity, or neuromuscular blockade, similar vigilance is required. ARIKAYCE also poses risks for embryo-fetal toxicity, potentially causing irreversible congenital deafness in pediatric patients exposed in utero. Patients must be monitored closely, and usage should be avoided with other drugs that increase the risk of neurotoxicity, nephrotoxicity, and ototoxicity.

ARIKAYCE is indicated for adults with Mycobacterium avium complex (MAC) lung disease, who have limited or no other treatment options, and have not achieved negative sputum cultures after at least six consecutive months of a multidrug regimen. The accelerated approval was based on reaching sputum culture conversion by the sixth month. The continuation of this approval depends on confirmatory trials verifying clinical benefits. The use of ARIKAYCE is not recommended for non-refractory MAC lung disease cases.

Insmed encourages patients to report any adverse effects to the FDA and provides contact information for further assistance. Full prescribing information is available for ARIKAYCE.

Insmed Incorporated, based in Bridgewater, New Jersey, is committed to enhancing the lives of patients with severe and rare conditions. The company has a diverse pipeline of investigational therapies aimed at neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed’s research extends to early-stage innovations involving technologies such as AI-driven protein engineering and gene therapy. Additional information about Insmed and its initiatives can be found on their website.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!